Search form

MASAC Recommendation Regarding the Need for Updated Guidelines for Diagnosis and Management of von Willebrand Disease

PrintFriendly

Printer Friendly and PDF

MASAC Recommendation Regarding the Need for Updated Guidelines for Diagnosis and Management of von Willebrand Disease

Date: 
September 21, 2014
MASAC Recommendation Regarding the Need for Updated Guidelines for Diagnosis and Management of von Willebrand Disease
ID: 
231
AttachmentSize
231VWDGuidelines2014.pdf89.98 KB
  • Von Willebrand disease (VWD) is a common, mild to severe bleeding disorder for which the diagnosis and treatment remain less than optimal. There are hereditary and acquired causes of von Willebrand Factor (VWF) deficiency, including abnormalities in both concentration and function. Since VWF is an integral part of the FVIII/VWF complex, VWD symptoms, in part, relate to VWF’s role in maintenance of FVIII activity and in the localization and physiological activation of clotting. This disorder is therefore within the purview of MASAC and the National Hemophilia Foundation.

     

    In 2007, NHLBI convened an advisory committee to develop guidelines for the diagnosis, evaluation, and management of VWD; they were finalized in 2008. (1) These guidelines were endorsed by multiple organizations, including the National Guidelines Clearinghouse (NGC), MASAC and ASH. After 5 years, these guidelines have now been withdrawn from the NGC, and NHLBI has decided not to update them.

     

    MASAC recognizes the critical need to maintain active, relevant guidelines concerning the diagnosis, evaluation, and management of VWF and to support the clinical needs of individuals with VWD and of individuals who are being evaluated for this disorder.

     

    MASAC therefore recommends that NHF convene a workshop to ascertain the needs of the patients, physicians, and scientists in order to update the guidelines and to establish the priorities for further development and active maintenance of these guidelines as needed.

     

    Reference

    1. Von Willebrand Disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.

     

    This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.

     

    Copyright 2014 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Director of Communications at 1-800-42-HANDI or visit the NHF website at www.hemophilia.org.